Journal info
|
||||
Select Journal
Journals
Bratislava Medical Journal 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Endocrine Regulations General Physiology and Biophysics Neoplasma Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Bratislava Medical Journal Vol.122, No.8, p.582–589,2021 |
||
Title: Impact of proactive low-molecular weight heparin therapy on outcomes in COVID-1 | ||
Author: S. Gormez, H. K. Gumusel, E. Ekicibasi, A. Degirmencioglu, A. Paudel, G. Akan, F. Atalar, R. Erdim, E. Eroglu, S. Dagdelen, N. Sariguzel, C. E. Kirisoglu, B. Pamukcu | ||
Abstract: OBJECTIVES: Low molecular weight heparin (LMWH) may provide beneficial effects on outcomes of COVID-19. We aimed to examine the impact of LMWH treatment on clinical outcomes (duration of hospitalization, admission to intensive care unit, the requirement for mechanical ventilation, and death) of COVID-19 patients with normal D-dimer levels at admission. BACKGROUND: Coronavirus disease-2019 (COVID-19) predisposes patients to arterial and venous thrombosis. METHODS: In this retrospective, multicentre and observational study we analysed the data of 308 confirmed COVID-19 patients with normal D-dimer levels at initial admission. After propensity score matching (PSM) patients were grouped; Group 1; patients who received LMWH with D-dimer ≤0.5 mg/L, Group 2; patients who received LMWH after D-dimer levels exceeded 0.5 mg/L, and Group 3; patients who did not receive LMWH. RESULTS: After PSM, each group comprised 40 patients. The patients in Group1 had the best clinical outcomes compared to the other groups. Group 3 had the worst clinical outcomes (p<0.005). The benefit of LMWH increased with early prophylactic therapy especially when started while the D-dimer levels were ≤0.5 mg/L. CONCLUSION: Our results strongly suggest that proactive LMWH therapy improves clinical outcomes in hospitalized COVID-19 patients even with normal D-dimer levels (≤ 0.5 mg/L) (Tab. 3, Fig. 2, Ref. 34). |
||
Keywords: COVID-19; SARS-CoV-2; thrombosis; antithrombotic therapy; low-molecular-weight heparin; D-dimer; enoxaparin | ||
Published online: 20-Jul-2021 | ||
Year: 2021, Volume: 122, Issue: 8 | Page From: 582, Page To: 589 | |
doi:10.4149/BLL_2021_093 |
||
|
![]() |
|